Novartis to pay Monte Rosa $150m upfront for MGD drug candidates
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
The world’s top 50 richest billionaires, with their private jets, yachts and polluting investments, produce more carbon pollution in over an hour than
GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to
A clinical-stage US gene-editing company, Precision BioSciences, got approval from the Eastern European country of Moldova to start an in vivo human trial
Multiple US agencies are investigating an outbreak of E. coli in the country, which was reported after eating Quarter Pounders hamburgers at McDonald’s,
HQ Team October 25, 2024: Researchers at the University of Waterloo have unveiled a nanomedicine that can deliver an entire course of antibiotics
HQ Team October 2, 2024: A device named Bioelectronic Localized Antimicrobial Stimulation Therapy (BLAST) has been developed to prevent skin infections by using harmless electrical
HQ Team October 25, 2024: A recent study indicates that a new slow-release ketamine pill could offer a promising alternative for individuals suffering